Search Results
Your search for them matches 6128 pages
Showing 4051 - 4100Management of Merkel Cell Carcinoma
A recent report regarding pembrolizumab (Keytruda) for advanced Merkel cell carcinoma ushered in a more optimistic era in the treatment of this rare but often lethal skin cancer.1 The ASCO Post spoke with one of the field’s leaders, Paul Nghiem, MD, PhD—the first author of the study—about the...
Continued ABVD vs Omission of Bleomycin (AVD) After Negative Imaging Findings in Advanced Hodgkin Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Peter Johnson, MD, of the Cancer Research UK Centre, University of Southampton, and colleagues found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs omission of bleomycin (AVD) after...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer...
Posttreatment Problems Surveyed in African American Breast Cancer Survivors
Although there is some overlap, past research has shown that the challenges faced by African American breast cancer survivors differ somewhat from Caucasian women. But the studies that demonstrated difference were not designed to explore those challenges in depth. Now new research from Thomas...
Does Intensified Postoperative Chemotherapy for High-Grade Osteosarcoma Benefit Poor Responders to Preoperative Therapy?
In a phase III trial (EURAMOS-1) reported in The Lancet Oncology, Marina et al found no improvement in event-free survival by adding postoperative ifosfamide/etoposide to cisplatin, doxorubicin, and methotrexate in patients with newly diagnosed high-grade osteosarcoma who responded poorly to...
Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma
In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...
Predictors of Readmission in Patients Requiring Free Tissue Reconstruction for Head and Neck Cancer
Certain factors increase the risk of unplanned readmission in the month after head and neck cancer resection requiring free tissue reconstruction, finds an analysis of data from the National Surgical Quality Improvement Program (NSQIP) of the American College of Surgeons.1 Nearly 1 in 10 patients...
Expert Point of View: M. Boyd Gillespie, MD, MSCR
“This study is actually surprising to me, because earlier studies of that particular antibody as a single therapy for this disease, salivary duct carcinoma, showed it was not very effective, with only 10% to 15% response rates,” session co-moderator, M. Boyd Gillespie, MD, MSCR, Professor and Vice ...
Use of Lugol’s Iodine Stain May Reduce the Need for Repeat Resection of Oral and Oropharyngeal Cancers
By identifying residual dysplasia in the tumor bed, Lugol’s iodine staining may improve pathologic outcomes with resection of oral and oropharyngeal cancers, according to interim findings of a UK randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1...
Palliative Care 2016: 'Mystery Shopper' Study Finds Barriers to Accessing Palliative Care Services at Major Cancer Centers
A team of researchers, using a novel approach, found that while many cancer centers offer palliative and supportive care services, patients may face challenges when trying to access them. The study showed that expanding awareness and education to patient-facing cancer center employees about such...
Gene Overexpression Scoring System May Accurately Predict Patient Response to Cancer Treatments
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) identified 14 genes regulating genome integrity that were consistently overexpressed in a wide variety of cancers. They then created a scoring system based upon the degree of gene overexpression. For...
Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In the phase III CASTOR trial reported in The New England Journal of Medicine, Palumbo et al found that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone markedly improved progression-free survival among patients with relapsed or relapsed and refractory...
Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer
A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...
Study Finds More Nodes Should Be Examined to Rule Out Node-Negative Disease in Papillary Thyroid Cancer
The proportion of patients with papillary thyroid cancer identified as having node-negative disease decreased substantially with an increased number of lymph nodes examined, according to an analysis of data from the National Cancer Database. Robinson and colleagues, of Duke University, reported...
Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer
Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...
Pitt Receives $62.3 Million, 5-Year NIH Award to Speed Up Translational Scientific Research Into Implementable Solutions
The University of Pittsburgh Clinical and Translational Science Institute (CTSI) will receive nearly $62.3 million over 5 years from the National Institutes of Health (NIH) to broaden its mission of speeding translation of scientific research into realistic treatments for the people who need them....
ASCO Unveils New Resources for MACRA Transformation
Are you ready for MACRA? Believe it or not, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed more than a year ago, and program changes begin in less than 6 months (January 1, 2017). MACRA will completely transform Medicare reimbursement and care delivery for oncology...
Surgical Oncologist Quan P. Ly, MD, FACS, Flees From Vietnam and Finds a Home at the University of Nebraska
After the Vietnam War, close to a million refugees, known as “boat people,” fled Vietnam, hazarding the open ocean on dangerously overloaded vessels. The term “boat people” is often used generically to refer to all the Vietnamese (about 2 million) who left their country by any means between 1975...
Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years
The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...
Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test
Receiving an invitation to undergo screening for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine.1 The study explored the impact of invitation and reminder letters on cervical cancer screening...
ASCO Endorses Cancer Care Ontario Recommendations on Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decisions in Early-Stage, Operable Breast Cancer
As reported in the Journal of Clinical Oncology (JCO) by N. Lynn Henry, MD, PhD, of University of Michigan Comprehensive Cancer Center, Ann Arbor, and colleagues,1 ASCO has endorsed Cancer Care Ontario guideline recommendations on the role of patient and disease factors in decisions on adjuvant...
Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated
The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer. HRT is used to treat...
Understanding Double-Hit Lymphomas and Optimizing Management
Double-hit lymphomas are a challenging subset of high-grade B-cell lymphomas, previously characterized histologically as diffuse large B-cell lymphoma or B-cell lymphoma unclassifiable with intermediate features between diffuse large B-cell lymphoma and Burkitt lymphoma. Expert guidance in their...
Late Cardiac Effects of Cancer Treatment
The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...
AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans
“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...
New Preclinical Study Shows Esophageal Cancers Driven by 'Marginal Gain' Rather Than Speed
Wellcome Trust Sanger Institute scientists have shown that unexpectedly, esophageal cancer cells do not divide faster than their normal neighbors. Unlike normal cells, however, the tumor cells produce slightly more dividing daughter cells than nondividing cells, forming a tumor. The study,...
Combination Obinutuzumab Regimen Active in Aggressive Diffuse Large B-Cell Lymphoma
In a small phase Ib/II study, 100% of patients with newly diagnosed diffuse large B-cell lymphoma evaluated thus far responded to treatment with obinutuzumab (Gazyva), lenalidomide (Revlimid), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), investigators from the University of...
Novel Approaches Harness the Microenvironment Against Hodgkin Lymphoma
In the treatment of classical Hodgkin lymphoma, antibodies targeting programmed cell death protein 1 (PD-1) are just the beginning, according to Stephen M. Ansell, MD, PhD, Professor of Medicine and Chair of the Lymphoma Group at the Mayo Clinic, Rochester, Minnesota.1 Speaking at the 2016 Pan...
Scalp Cooling for Chemotherapy-Induced Alopecia Becoming Mainstream
Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration (FDA) approval of the DigniCap Cooling System and the growing acceptance of scalp-cooling methods in the United States may improve the quality of life for many patients receiving...
New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia
According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia (CLL), novel agents and new data on patient subsets have led to a new upfront treatment algorithm for this malignancy. Speaking at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, Dr. O’Brien...
Expert Point of View: Amir T. Fathi, MD
Amir T. Fathi, MD, an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School, Boston, commented on the INO-VATE ALL trial for The ASCO Post. “It has been a fairly exciting time for patients with acute lymphoblastic leukemia...
Study Links F12 and STC2 Genes to Breast Cancer Survival
Testing for the activity of two genes could help identify women who are at increased risk of dying from breast cancer, according to a new study of almost 2,000 patients. Women whose tumors had a specific pattern of activity in the F12 and STC2 genes were three times as likely to die within 10 years ...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling, or COMET (EAQ152), to the NCI-MATCH (EAY131) trial already underway. Using feedback surveys before and after a patient undergoes tumor gene...
Preclinical Study Finds Etoposide May Damage Developing Ovaries of Female Fetuses
The chemotherapy drug etoposide may have adverse effects on the developing ovaries of female fetuses, according to a preclinical study of mouse cells published by Stefansdottir et al in BMC Cancer. Norah Spears, DPhil, the corresponding study author and Professor of Reproductive Physiology at the...
Report Tracks Cancer Trends by Race/Ethnicity in Los Angeles County for 37 Years
Prostate cancer and lung cancer have been the number 1 and 2 cancers among men. Stomach cancer, the third leading cause of cancer deaths worldwide, has been on a steady decline among Koreans and Japanese. Black men had the highest overall rates of cancer. Thyroid cancer has been on the rise, and...
Needle Biopsies for Noninvasive Breast Cancer: Routine Analysis Wastes Millions
For patients with the most common type of noninvasive breast cancer, routine testing for estrogen and progesterone receptors in tissue taken at the first needle biopsy is both unnecessary and wasteful, according to results of a study led by Johns Hopkins pathologists. The results for people with...
Metabolic Imaging as a Method to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Tumor shrinkage is not the only measure of a successful anticancer therapy. A University of Colorado Cancer Center article published by Serkova et al in Frontiers in Oncology describes a promising alternative: metabolic imaging. Tumors rush their metabolism to grow and proliferate. By recognizing a ...
New American Cancer Society Cancer Action Network Report Shows States Are Making Progress Implementing Policies to Reduce Toll of Cancer
Although a majority of states are still missing important opportunities to pass and implement legislative solutions proven to prevent and fight cancer, there is progress being made to move the nation closer to ending cancer as we know it, according to a report recently released by the American...
Chinese Journal of Cancer Collecting 150 Most Important Questions in Cancer Research and Clinical Oncology
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making
Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...
Multiple Means to Realize the Benefits of Colorectal Cancer Screening
In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults aged 50 through 75; but rather than emphasize specific screening strategies, it notes there are multiple screening...
Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test
Receiving an invitation to get screened for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine. The study explored the impact of invitation and reminder letters on cervical cancer screening...
A Ruby Anniversary
On July 16, 1975, at 26 years of age, after almost 6 months of observing a left epididymal mass slowly enlarge, with workup for epididymal tuberculosis, I finally underwent a left inguinal orchiectomy and resection of what proved to be a pure seminoma. A subsequent lymphangiogram was reported to...
Reference Laboratory Identifies Change in Pattern of Breast Cancer HER2 Fluorescence in Situ Hybridization Results
The most recent (2013) ASCO/College of American Pathologists (AC) guidelines for HER2 testing resulted in different rates of HER2 positivity compared with the use of the U.S. Food and Drug Administration (FDA) or 2007 AC guidelines, according to a study reported in the Journal of Clinical Oncology...
Measures of Success
I was raised to be an engineer. I grew up in an industrial community, worked summer jobs in a U.S. Steel chemical plant, and was good at science and math. My career choice was straightforward: I went to an engineering university. My first semester freshman year included a mandatory introduction...
Integrating Early Palliative Medicine Into Oncology Care to Improve Patients’ Quality of Life
At the 2015 Palliative Care in Oncology Symposium in Boston, Vicki Jackson, MD, MPH, Chief in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital, Co-Director of the Harvard Center for Palliative Care, and Associate Professor of Medicine at Harvard Medical School,...
Epithelial Cells on the Tail Fin of Genetically Engineered Zebrafish
Image depicts hundreds of live cells from a tiny bit of skin on the tail fin of a genetically engineered adult zebrafish. The cells have been labeled with a new fluorescent imaging tool called Skinbow. It uniquely color codes cells by getting them to express genes encoding red, green, and blue...
New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade
American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1 Small Percentage Responsible for...
Educating People About Clinical Trials May Improve Their Likelihood of Participation
The facts are well known: Although clinical trials are regarded as the gold standard to investigate whether a new treatment is safe and effective in patients—and have resulted in advances in cancer cures and increases in cancer survivorship—only 3% to 5% of patients enroll in these studies.1 The...
OmniSeq Receives New York CLEP Approval for 144-Gene Comprehensive Panel, Partners With Cure Forward
OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive panel, a 144-gene, pan-cancer, next-generation sequencing tumor-profiling diagnostic panel to guide oncology treatment...
